A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
Condition(s):Hematological MalignanciesLast Updated:September 1, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Hematological MalignanciesLast Updated:September 1, 2023Active, not recruiting
Condition(s):Hematological MalignanciesLast Updated:July 28, 2023Active, not recruiting
Condition(s):Hematological MalignanciesLast Updated:February 5, 2024Recruiting
Condition(s):Bloodstream InfectionLast Updated:May 16, 2023Completed
Condition(s):Hematologic MalignancyLast Updated:February 8, 2024Recruiting
Condition(s):Cognitive Impairment; Haematological Malignancy; Chemo-brainLast Updated:December 17, 2020Unknown status
Condition(s):ChildLast Updated:April 19, 2022Recruiting
Condition(s):Hematologic MalignanciesLast Updated:November 1, 2018Completed
Condition(s):Hematologic MalignancyLast Updated:November 14, 2023Completed
Condition(s):Hematologic MalignanciesLast Updated:April 6, 2012Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.